A trial date in NVS/MNTA’s patent-infringement suit vs Teva is provisionally set for February 4, 2013. That’s not a typo!
I continue to stand by the following statment from #msg-60638698, which was posted a few weeks ago:
We may presume that NVS/MNTA would ask the Court for a preliminary injunction against Teva in the event that Teva were to get FDA approval for generic Lovenox. Therefore, the fact that Teva has agreed to a drawn-out timeline in which a trial could not start until 2013 suggests that Teva has no expectation of getting FDA approval in the next two years. For readers of this board, this is hardly surprising, of course.
Here is the document filed with the District Court today:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.